11 September 2012: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
Trial reference:
A multi-center, randomized, double-blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination of HIV-1 clade B infected patients under highly antiretroviral therapy